Our advisory panel
Professor Ross McKinnon is the Director of Flinders Centre for Innovation in Cancer and Associate Dean Research in the School of Medicine at Flinders University. He is also a Vice-President of the International Pharmaceutical Federation (FIP). As an academic pharmacist, Ross has broad research interests in the pharmacology, pharmaceutical biotechnology and molecular oncology areas.
Dr Lowy is a surgical oncologist with a primary interest and experience in cancers of the pancreas. He is recognised worldwide for his expertise in the surgical treatment of Pancreatic Cancer and for investigating novel cancer treatments in patients with advanced cancer that has spread to the abdomen. Dr. Lowy is on the editorial board of the Annals of Surgical Oncology and is the co-chair of the National Cancer Institute’s Pancreatic Cancer Task Force. He serves as the surgical principal investigator in the largest pancreatic cancer clinical trial ever conducted in the United States.
Lorraine completed her UNSW Phd in 2015 at The Garvan Institute of Medical Research/St Vincent’s Clinical School and was recently appointed Senior Staff Specialist Medical Oncologist at St Vincent’s Hospital. She is the Clinical Lead for Oncology Clinical Trials at St Vincent’s and is the Principal Investigator on several clinical trials in gastrointestinal cancers. Lorraine is a Director of the Australasian Gastrointestinal Trials Group (AGITG) and Chairs the Upper GI working party of the AGITG. She is an executive member of the Australian Pancreas Cancer Genome Initiative (APGI).
Dr Chen is a HepatoPancreatoBiliary and Liver Transplant Surgeon at Flinders Medical Centre and Royal Adelaide Hospital. He is also the Director of South Australian Liver Transplant Unit at Flinders Medical Centre. Dr Chen's research interests include pancreatic, biliary and liver malignancies.
Dr O’Reilly is a Medical Oncologist and Researcher who’s initiatives include the integration of molecular and genetic-based therapies into the treatment of pancreas cancer, developing adjuvant and neoadjuvant therapies, and identifying biomarkers that may be used to select therapy. She is the principal investigator of multiple phase I, II, and III clinical trials in pancreas cancer and has authored and co-authored many articles, editorials, and book chapters. Within the United States, Dr O’Reilly holds several prominent national positions for Pancreatic Cancer including: Chair of the Alliance GI Committee, Membership of the Gastrointestinal Cancers Steering Committee, and also serves on the Scientific and Medical Advisory Board of the Pancreas Cancer Action Network and the National Pancreas Foundation.